Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug regorafenib tested to halt bone sarcoma spread

NCT ID NCT02389244

Completed Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether the drug regorafenib can stop or slow the growth of metastatic bone sarcomas (cancers that started in bone and spread). 163 patients with osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma are randomly assigned to receive regorafenib or a placebo. The main goal is to see how many patients have no disease progression after a set time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Regorafenib (Stivarga), a cancer drug taken as tablets
What this could lead to
If it works, this could offer a new treatment option to slow the growth of metastatic bone sarcomas.
What could go wrong
This is a mid-stage trial with a modest size, so results may not confirm benefit. Regorafenib can cause side effects like fatigue, diarrhea, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHONDROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chondroma chondrosarcoma chordoma CIC-rearranged sarcoma Ewing sarcoma Ewing sarcoma of bone osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHONDROMA CHONDROSARCOMAS CIC-REARRANGED SARCOMA EWING SARCOMAS OSTEOSARCOMAS

Contacts and locations

Locations

  • CHU Bretonneau

    Tours, 37000, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Eugene Marquis

    Rennes, 35042, France

  • Centre Francois Baclesse

    Caen, 14176, France

  • Centre Georges Francois Leclerc

    Dijon, 21079, France

  • Centre Léon Berard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Gustave Roussy

    Villejuif, 94800, France

  • Hopital Jean Monjoz

    Besançon, 25030, France

  • Hôpital Cochin

    Paris, 75014, France

  • ICM Val d'Aurelle

    Montpellier, 34298, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut Claudius Regaud

    Toulouse, 31052, France

  • Institut Curie

    Paris, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Institut de Cancérologie Lucien Neuwirth (ICLN)

    Saint-Priest-en-Jarez, 42270, France

  • Institut de cancerologie de l'ouest site Rene Gauducheau

    Saint-Herblain, 44805, France

  • Institut de cancerologie de lorraine alexis Vautrin

    Vandœuvre-lès-Nancy, 54519, France

  • La Timone University Hospital

    Marseille, 13385, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.